About AbCellera Biologics
AbCellera focuses on discovering and developing therapeutic antibodies for various diseases. The company uses a proprietary technology platform that combines different scientific methods to identify and create antibodies efficiently. Clients, including pharmaceutical companies and research institutions, partner with AbCellera to enhance their drug development processes. Unlike many competitors, AbCellera excels at addressing challenging targets that traditional methods struggle with. The company's goal is to advance new treatments to market while generating revenue through partnerships, discovery services, and licensing its antibody candidates.
Vancouver, CanadaHeadquarters
2012Year Founded
$620.9MTotal Funding
IPOCompany Stage
AI & Machine Learning, Biotechnology, HealthcareIndustries
501-1,000Employees
Benefits
Paid Vacation
Paid Sick Leave
Flexible Work Hours
Company Equity
Performance Bonus
Risks
Peter Thiel's resignation may impact strategic guidance and investor confidence.
High-risk research with Biogen could lead to delays or failures.
Resource allocation challenges may arise from multiple new biotech ventures.
Differentiation
AbCellera's platform integrates diverse scientific approaches for efficient antibody discovery.
The company excels in tackling challenging targets with innovative methods.
AbCellera's strategic partnerships enhance its antibody development capabilities.
Upsides
Collaboration with Biogen could lead to breakthroughs in neurological treatments.
Partnership with Eli Lilly expands AbCellera's reach in diverse therapeutic areas.
Acquisition of Dualogics' platform strengthens AbCellera's competitive position.
Funding
Total raised$620.88 M
Latest valuation$720.00 M
StageIPO
IPO
11/30/2020$556
$106
$720.00 MSERIES A
8/31/2018$10
$50.00 MEARLY VC
3/31/2017$1
$4.09 M